ArticleFrontiers in pharmacology2026
Predictive value of ALBI score and age for developing resistance to trastuzumab in HER-2-positive breast cancer patients: prediction based on a real-world case series from a single center in China.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the clinical value of the ALBI score and age in predicting trastuzumab resistance in patients with HER-2 positive breast cancer (BC). Methods: A retrospective cohort study was conducted on patients with HER-2 positive BC treated with trastuzumab at the Department of Thyroid and Breast Surgery of Affiliated Hospital of Shandong University of Traditional Chinese Medicine from December 2017 to December 2023. Patients were divided into a resistance group and a non-resistance group based on the development of resistance after trastuzumab treatment. Multivariate logistic regression models were used to identify independent predictors of trastuzumab resistance, and ROC curves analysis was conducted to evaluate the predictive value of ALBI score and patients age. Results: This study included 95 female patients with HER-2 positive BC treated with trastuzumab, aged 31-71 years (mean age 53.15 ± 10.063 years). Based on the development of resistance after trastuzumab treatment, patients were divided into a resistant group (11 cases, 11.6%) and a non-resistant group (84 cases, 88.4%). Compared with the non-resistant group, the resistant group showed significantly higher age, ALBI score, and carcinoembryonic antigen (CEA) levels ( Conclusion: Both ALBI score and age are independent predictors influencing trastuzumab resistance in HER-2 positive BC patients. Their combined use enhances predictive accuracy and may facilitate early identification of patients at increased risk of developing resistance to trastuzumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.